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In order to elucidate the molecular basis of microRNA let-7a-1/let-7f-1 gene cluster, the transcription 
initiation site which was determined by 5’ rapid amplification of cDNA ends (5’RACE) and 2.1 kb of the 
5' flanking region proximal to the pre-let-7a-1 was isolated and characterized. The promoter activity of 
the 2.1 kb fragment was analyzed by a firefly luciferase-encoding gene expression vector (pGL3) 
transiently transfected into lung cancer cell line A549. The 2.1 kb promoter of let-7a-1/let-7f-1 displayed 
a lower activity and was significantly enhanced by ectopic expression of c/EBPα or p53 and treatment 
with dexamethasone. Despite the induction of other let-7 family members such as let-7a-3, let-7c and 
let-7d, all-trans retinoic acid (ATRA) and 9-cis retinoic acid (9cRA) display little enhancement effect on 
2.1 kb promoter of let-7a-1/let-7f-1, as well as 1,25-(OH)2D3.  
  





MicroRNAs (miRNAs) are non-coding small RNAs found 
in diverse organisms (Chen, 2005; Hammond, 2006). 
They are encoded in long primary forms in the nucleus 
(pri-miR). The pri-miRs will be transported into the 
cytoplasm after being processed to 70 to 80 nucleotide 
pre-miR with a characteristic hairpin structure. The pre-
miR are then processed by Dicer into the 22 to 25 nt 
mature forms (Lee et al., 2002). miRNAs mediate gene 
down-regulation by targeting mRNAs to induce RNA 
degradation and/or interfering with translation and thus, 
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(Ambros, 2003). Concordant with this, aberrant 
expression of miRNA genes could lead to human 
disease. In recent years, many reports have shown that 
miRNAs regulate cell proliferation and apoptosis and play 
a role in cancer: microRNAs can act as oncogenes or 
tumor suppressors (Chen, 2005; Hammond, 2006).  
There are accumulating evidences that let-7, the first 
discovered miRNA, is tumor suppressor. A number of 
studies have demonstrated that let-7 was implicated in 
various cancers, particularly in lung cancer (Eder and 
Scherr, 2005; Lu et al., 2007; Sampson et al., 2007; 
Motoyama et al., 2008). Takamizawa et al. (2004) first 
reported that the expression of the let-7 microRNA was 
reduced in human lung cancers and overexpression of 
let-7 in A549 lung adenocarcinoma cell line inhibited lung 
cancer cell growth in vitro. Next, Johnson et al. (2005 
identified that ras is one of the target genes of let-7 
family. Lee and Dutta (2007) also found that let-7 
repressed the HMGA2 oncogene in human lung cancer 
cells. Therefore, let-7 is tumor suppressor microRNA and 
maybe a potential target for lung cancer therapy.  Despite  




this interest, the underlying molecular mechanisms of let-
7 reduction in lung cancer are not well understood. The 
qRT-PCR results from different investigators have shown 
the significant down-regulation of pri-let-7 in lung cancer 
tissues and cells (Takamizawa et al., 2004; Yanaihara et 
al., 2006), suggesting the inhibition on transcription level 
maybe one of the mechanisms for let-7 expression 
reduction in lung cancer. But our understanding of let-7 
transcription pattern in lung cancer cells is limited. Thus, 
cloning and characterization of the 5' flanking region of 
let-7a-1 and let-7f-1, which are the most abundant 
species of let-7 family and clustered within a few hundred 
bases in the human genome (Lagos-Quintana et al., 
2001), may well be a start point for elucidating the 
transcription regulation mechanism of let-7. 
 
 




The human lung cancer cell line A549 (ATCC- American Type 
Culture Collection) were cultured with F-12K (Gibco, BRL 
Gaithersburg, MD, USA) medium containing 10% fetal bovine 
serum, plus 100 u/ml ampicillin and 100 u/ml streptomycin at 37°C 
with 5% CO2. Within 24 h of passage, cells with more than 70 to 
80% confluence were used for transfection. 
 
 
Mapping the transcription start site of let-7a-1/let-7f-1 gene 
cluster 
 
The start of transcription of the let-7a-1/let-7f-1 gene cluster was 
determined by the 5’ rapid amplification of cDNA ends (5’RACE) 
protocol using a 5’/3’ RACE kit essentially as recommended by the 
manufacturer (Roche Diagnostics, Laval, Quebec, Canada). Total 
RNA was prepared from lung cancer cell strain A549 and then 
treated with RNase-free DNase. Total RNA (2 µg) in a 20 µl 
reaction volume was reverse transcribed at 55°C with transcriptor 
reverse transcriptase and let-7a-1/let-7f-1 cluster-specific primer 
SP1 (5’- TAATGCAGCAAGTCTACTCCTCAGGG -3’). A homopo-
lymeric tail was appended to the 3’ end of the synthesized first-
strand cDNA using terminal transferase and dATP by incubation at 
37°C for 20 min as described in the kit protocol. The dA-tailed 
cDNA was PCR amplified using an oligo (dT)-anchor primer (5’- 
GACCACGCGTATCGATG TCGACTTTTTTTTTTTTTTT TV-3’) and 
another let-7a-1/let-7f-1 cluster-specific primer SP2 (5’- 
CCCCACAACTATACAATCTACTACCTCACTC- 3’). The PCR 
product obtained was again PCR amplified with the nested let-7a-
1/let-7f-1 cluster-specific primer SP3 (5’- CCGCCTGGATGCAGAC 
TTTTCTATC -3’) and a kit-provided PCR anchor primer (5’- 
GACCACGCGTATCGATGTCGAC-3’) in order to eliminate any 
nonspecific PCR products from the first reaction. The amplified 
products were purified using a high pure PCR product purification 
kit (Roche) and cloned into the pMDT-18 vector (Takara 
Biotechnology, Dalian, China). Automated DNA sequencing of the 




Amplifying and cloning a 2.1 kb fragment of the 5’ flanking 
region of the let-7a-1/let-7f-1 gene cluster 
 





the method of rapid isolation of mammalian DNA. The primer pair 
PF (5’- CCGCTCGAGACCCAGCCATGTTCAGTTCT -3’; with an 
Xho I site at its 5’ end) and PR (5’- CCCAAGCTTCAGTGAA 
GAGAACATCCAGG-3’; with a Hind III site at its 5’ end) were used 
to amplify the 5’ flanking region of the let-7a-1/let-7f-1 gene cluster 
from the extracted human genomic DNA by PCR. The PCR-
amplified fragment was 2123 bp (-1999 to +124 bp) and it was 
excised with Xho I and Hind III (TaKaRa) and ligated into the 
equivalent site of the pGL3-Basic vector (Promega, Madison WI, 
USA) to form the let-7a-1/let-7f-1 cluster promoter-luciferase 
reporter construct, designated pGL3-2123. The resulting construct 
was confirmed by restriction enzyme digestion and sequence 





A549 cells in 70 to 80% of confluence were transfected with 
Fugene HD (Roche) in 24-well plates. Each well contained 0.5 µg 
pGL3-2123, 0.02 µg of the internal control vector pRL-TK, 1 µl 
Fugene HD and 500 µl F-12K medium without serum or antibiotics. 
For co-transfection experiments, 0.3 µg pGL3-2123 was transfected 
along with 0.2 µg of one of the eukaryotic expression plasmids 
pCMV-p53 (Clontech, Palo Alto, CA), pcDNA3.1-Sp1 and 
pcDNA3.1-NFκBp50 (gifts from Dr. Charles Young, Mayo clinic, 
USA), pcDNA3.1-PPARγ2, pcDNA3.1-c/EBPα (gifts from Dr. 
Jianhua Shao, University of Kentucky, USA), pBABEpuro-ras or 
pBABEhygro-myc (gifts from Dr. Weijing He, University of Texas, 
USA). All the cells underwent the dual-luciferase reporter assay 48 
h after the completion of the transfection procedure, following the 
protocol recommended by Promega. 
 
 
Treatment of the transfected cells with hormones 
 
The stocks of all-trans retinoic acid (ATRA), 9-cis-retinoic acid 
(9cRA) and 1,25-dihydroxyvitamin D3 (1,25(OH)2D3) were prepared 
in dimethylsulfoxide (DMSO); the stock of dexamethasone (DEX) 
were prepared in ethanol. All of the hormones were purchased from 
Sigma (St. Louis, MO, USA). After the transfection of pGL3-2123 in 




 M of 
ATRA, 9cRA, 1,25(OH)2VitD3 or DEX in 10% FBS-F-12K medium, 
respectively. The controls received the DMSO or ethanol vehicle at 
a concentration equal to that of the treated cells. All the cells 
underwent the dual-luciferase reporter assay 48 h after the 
completion of the treatment procedure. 
 
 
Dual-luciferase reporter assay 
 
The activities of firefly luciferase in pGL3 and Renilla luciferase in 
pRL-TK (Promega) were determined following the dual-luciferase 
reporter assay protocol recommended by Promega. The cells were 
rinsed with PBS after harvest and cell lysates were prepared by 
manually scraping the cells from the culture plates in the presence 
of 1×PLB (passive lysis buffer). 20 µl of cell lysate was transferred 
into luminometer tubes containing 100 µl LAR. Firefly luciferase 
activity (M1) was measured first and then Renilla luciferase activity 






Data are expressed as mean ± SD of at least three independent 
experiments. Statistical significance of differences  between  groups  






Figure 1. Map the 5’ end of primary transcript of the let-7a-1/let-7f-1 cluster. The 
transcription start site detected by 5’ RACE is boxed and numbered +1. The primers used 
for 5’RACE (SP1-3) are shaded in gray. The lines and arrows indicate the pre-miR 






Figure 2. Activity assay of pGL3-2123 in A549 cells. pGL3-2123 
was transfected into A549 cells along with a negative control 
pGL3-Basic and a positive control pGL3-Control. The promoter 
activities were determined via the dual-luciferase reporter assay. 
The results are expressed as the relative luciferase activities 
(M1/M2), that is, the ratio of firefly luciferase activity (M1) in the 
pGL3 plasmid and Renilla luciferase activity (M2) in the pRL-TK 
plasmid. 




was analyzed by unpaired Student's t test and P < 0.05 was 
considered to be statistically significant. 
 
 
RESULTS AND DISCUSSION 
 
Mapping the transcription start site of let-7a-1/let-7f-1 
gene cluster 
 
Many evidences have indicated that microRNA genes are 
transcribed by RNA polymerase II (Tam, 2001; Johnson 
et al., 2003; Xie et al., 2005) and a handful of miRNA 
promoters in Homo sapiens have been identified so far 
(Lee et al., 2004; Houbaviy et al., 2005). According to 
MiRBase data, the hsa-let-7 family has 11 members that 
distribute on different chromosomes. Searching result 
from Entrez gene indicate that the let-7a-1 and let-7f-
1gene is an intergenic cluster located within chromosome 
9q22.32 (Gene ID: 406881) (Figure 1). To determine the 
transcription initiation site of let-7a-1/let-7f-1 cluster, 
5’RACE was performed using RNA isolated from A549 
cells and three let-7a-1/let-7f-1 cluster-specific primers 
(SP1-3). As shown in Figure 1, let-7a-1/let-7f-1 cluster 
has single transcription initiation site, located at 124 bp 
upstream the pre-let-7a-1.  
 
 
Cloning and activity assay of the 2.1 kb promoter 
fragment of let-7a-1/let-7f-1 cluster 
 
Based on the result of 5’RACE, starting 2.1 kb upstream 
of pre-let-7a-1, a genomic fragment including positions -
1999 to +124 relative to the transcription start site was 
cloned into the pGL3-Basic to form pGL3-2123, which 
was confirmed by DNA sequencing. To evaluate the 
promoter activity, the pGL3-2123 was transfected into 
lung cancer cell line A549, pGL3-Control and pGL3-Basic 
were also introduced into parallel wells, respectively, as 
positive and negative controls. The luciferase activity was 
assayed and normalized to pRL-TK (Figure 2). After 48 h 
of transfection into A549 cells, pGL3-2123 yielded a 
result of 5.24 by dual-luciferase reporter assay (M1/M2). 
Comparing with respective 38.76 of pGL3-Control 
and0.26 of pGL3-Basic, the 2.1 kb promoter of let-7a-
1/let-7f-1 cluster display a lower activity in A549 cells, 
which was consistent with the fact that A549 cell line has 
the reduced expression of endogenous let-7a-1/let-7f-1 
(Takamizawa et al., 2004), suggesting the inhibition of 
promoter may be one of the reasons for reduced 
expression of let-7a-1/let-7f-1 in lung cancer cells. 
 
 
The effect of some tumor-associated transcription 
factors on promoter activity of pGL3-2123  
 
As class-II genes, expressions of many microRNAs are 





Lagos-Quintana et al., 2001) or hormones (Lee et al., 
2002). Computer-based analysis of this 2.1 kb 5’-flanking 
fragment sequence with MatInspector 2.0 software 
(http://www.genomatix.de), three putative TATA-boxes (-
414/-398, -366/-344 and -110/-94) and two CCAAT –
boxes (-118/-104 and -314/-300) were searched within 
the -1000/+1 region. In addition, more than 700 other 
putative transcription factor binding sites (Matrix similarity 
> 0.75) were searched by MatInspector within the 2.1 kb 
fragment. Because let-7a-1/let-7f-1 cluster is tumor 
suppressor miRNAs, we are interested in the tumor-
associated transcription factor binding sites. The 
computer search result displayed four c/EBP sites (-
1726/-1712, -1683/-1669, -722/-708 and -163/-149), two 
PPAR sites (-1434/-1412 and -533/-511), one NF-κB site 
(-1255/-1243), two Sp1 sites (-1953/-1933 and -1008/-
988) and two P53 sites (-1170/-1148 and -1159/-1137). In 
order to investigate whether the putative cis-elements 
mentioned earlier have functions, the eukaryotic 
expression plasmids of c/EBPα, PPARγ2, NF-κB p50, 
Sp1 and p53, were co-transfected with pGL3-2123 into 
A549 cells and the corresponding empty eukaryotic 
expression vectors of themselves were co-transfected 
with pGL3-2123 into parallel wells as a control. In 
addition, because the oncogenes ras and myc are targets 
of let-7 (Boominathan, 2010), the co-transfection of ras 
/myc expression vector with pGL3-2123 were also 
performed to test whether the let-7 and ras/myc share a 
feedback loop. The relative luciferase activities from 
pGL3-2123 co-transfected with eukaryotic expression 
plasmids was divided by the relative luciferase activity 
from pGL3-2123 co-transfected with control vector from 
the same cell line and plotted in Figure 3. Our results 
indicate that ectopic expression of PPARγ2, NF-KappaB, 
Sp1, ras and myc have no significant effect on pGL3-
2123 promoter activity, whereas c/EBPα and p53 
increases the promoter activity of pGL3-2123 about 3.6-
fold and 2.0-fold, respectively.  
c/EBPα, one member of the c/EBP family, is a gene 
thought to be a tumor suppressor (Timchenko et al., 
1996; Lekstrom-Himes and Xanthopoulos, 1998; Pabst et 
al., 2001). As a transcription factor, c/EBPα is discovered 
controlling the transcription of some tumor suppressor 
microRNA. Recently, the c/EBPα is reported to directly 
interacted with the mir-122 (hepatocyte-specific 
microRNA) promoter and transactivate it (Zeng et al., 
2010). Studies in acute myeloid leukemia (AML) have 
shown that mir-34a and mir-223 were transcriptional 
targets of c/EBPα (Pulikkan et al., 2010, 2010). In A549 
and H1299 lung cancer cells, the ectopic c/EBPα 
expression increases expression of mir-1 6.1-fold and 
4.92-fold, respectively (Nasser et al., 2008). mir-661, 
which can inhibit metastatic tumor antigen 1, is another 
c/EBPα target (Reddy et al., 2009). In our experiment, the 
expression of ectopic c/EBPα significantly increase the 
promoter activity of let-7a-1/ let-7f-1 cluster (3.6-fold) in 
A549 cells with little endogenous  c/EBPα  expression  (Li  






Figure 3. The effects of some transcription factors on promoter activities of let-7a-
1/ let-7f-1 cluster. A549 cells were co-transfected with pGL3-2123 and eukaryotic 
expression plasmids of c/EBPα, PPARγ2, NF-κB p50, Sp1, p53, ras or myc. The 
control cells were co-transfected with pGL3-2123 and corresponding empty 
eukaryotic expression plasmids. All the cells were harvested for the dual-luciferase 
reporter assay after 48 h of transfection. The results were expressed as ratio of 
relative activity, that is, the M1/M2 value from pGL3-2123 co-transfected with 
eukaryotic expression plasmids was divided by the M1/M2 value from controls. **P 




et al., 1995), suggesting that the let-7a-1/ let-7f-1 cluster 
is a new transcriptional target of c/EBPα. 
p53 is a broad-spectrum tumor suppressor gene that 
plays very important roles in various cancers. The P53 
protein functions as transcription factor to transactivate 
expression of a number of target genes to promote tumor  
suppression and genome integrity. Recently, a number of 
studies have shown that many miRNAs are also 
members of p53-network. For example, mir-34, mir-
192/215, mir-107 and mir-145, all of which function as 
tumor suppressors and play a key role in control of tumor 
progression, angiogenesis and metastasis, are shown to 
be direct transcriptional targets of p53 (Hermeking, 2007; 
Tarasov et al., 2007; Boominathan, 2010). Besides mir-
34a, Tarasov et al. (2007) also observed that activation of 
p53 in lung cancer cells results in increased expression 
of mature-let-7c (2.7-fold), mature-let-7e (2.1-fold) and 
mature-let-7a (1.9-fold). Our results further suggest that 
p53 increase the expression of let-7a-1/let-7f-1 at 
transcriptional level, but maybe due to the endogenous 
expression of wt p53 by A549 cells (Jia et al., 1997), the 
ectopic expression of p53 had a weaker increase effect 
on let-7a-1/let-7f-1 promoter than that of c/EBPα. 
 
 
The effects of hormones on promoter activity of let-
7a-1/ let-7f-1 cluster 
 
Besides the transcription  factors  mentioned  earlier,  two  
RAR-RXR heterodimer binding sites (-46/-22 and 
+90/+114), four VDR-RXR heterodimer binding sites (-
1955/-1931, -1691/-1667, -1600/-1576 and -1592/-1568), 
three glucocorticoid responsive and related elements 
(GRE) (-1877/-1859, -1588/-1561 and -1416/-1398) were 
detected by MatInspector 2.0 software. The RAR (retinoic 
acid receptor), RXR (retinoid X receptor) and VDR 
(Vitamin D3 receptor) belong to the nuclear receptor 
superfamily of ligand-inducible transcription 
(Stunnenberg, 1993). The RAR and RXR mediate the 
effect of retinoids signals such as all-trans-RA (ATRA) 
and 9-cis- RA (9cRA), which influence processes such as 
growth and differentiation by regulation of target gene 
expression at the cellular level (Gudas, 1994). Retinoids 
suppress carcinogenesis in diverse epithelial tissues 
including lung. Clinical trials have demonstrated the 
efficacy of retinoids in suppressing lung cancer (Aapro, 
1995). Several lines of evidence have shown that 
treatment with retinoic acid not only down-regulate 
miRNAs that function as oncogenes, but also up-regulate 
tumor suppressor miRNAs including members of let-7 
family (Garzon et al., 2007; Careccia et al., 2009; Weiss 
et al., 2009). For example, acute promyelocytic leukemia 
(APL) successfully treated with ATRA showed 
upregulation of let-7c (Careccia et al., 2009), as well as 
Garzon et al. (2007) found up-regulation of let-7a-3, let-
7c and let-7d by miRNA microarrays and qRT-PCR in 
APL patients and cell lines during ATRA treatment. To 
explore    whether   the  retinoic   acids  are  implicated  in  






Figure 4. The effects of 9cRA and ATRA on promoter activity of let-7a-1/ let-7f-1 cluster. A549 cells transfected with pGL3-




 M of 9cRA and ATRA for 48 h, as well as parallel wells transfected with pGL3-Basic as 
negative control. The cells were harvested for the dual-luciferase reporter assay to detect the effects of hormones on 






Figure 5. The effects of 1,25(OH)2D3 on promoter activity of let-
7a-1/ let-7f-1 cluster. A549 cells transfected with pGL3-2123 




 M of 1,25(OH)2D3 for 48 h, as well 
as parallel wells transfected with pGL3-Basic as negative 
control. The cells were harvested for the dual-luciferase reporter 
assay to detect the effects of hormones on promoter activity of 
the let-7a-1/ let-7f-1 cluster. The results were expressed as 




controlling expression of let-7a-1/ let-7f-1 cluster, the 





 M of 9cRA or ATRA for 48 h. As shown in 
Figure 4, the 2.1 kb promoter activity of let-7a-1/ let-7f-1 
cluster did not display significant increase after treatment 
with 9cRA as well as ATRA. 
The VDR, upon activation by 1,25(OH)2D3, forms a 
heterodimer with the RXR and binds to corresponding 
hormone response elements on DNA resulting in 
expression of specific geneproducts (Stunnenberg, 
1993). 1,25-(OH)2D3 exerts important effects on cellular 
proliferation and differentiation and has been shown to 
decrease the growth of many cancers (Walters, 1992; 
Campbell et al., 1997). To date, a few studies have 
revealed the interaction between 1,25-(OH)2D3 signal 
pathway and miRNAs (Mohri et al., 2009; Essa et al., 
2010; Xi et al., 2010). In our study, 1,25-(OH)2D3, like 
retinoic acids, have no significant effect on 2.1-kb 
promoter of let-7a-1/ let-7f-1 cluster (Figure 5), 
suggesting the little possibility that the  expression  of  let- 






Figure 6. The effects of DEX on promoter activity of let-
7a-1/ let-7f-1 cluster. A549 cells transfected with pGL3-




 M of DEX for 48 h, as 
well as parallel wells transfected with pGL3-Basic as 
negative control. The cells were harvested for the dual-
luciferase reporter assay to detect the effects of hormones 
on promoter activity of the let-7a-1/ let-7f-1 cluster. The 
results were expressed as ratio of relative luciferase 




7a-1/ let-7f-1 cluster is regulated by retinoic acid or 1,25-
(OH)2D3 at transcriptional level. 
Despite the 1,25-(OH)2D3 and retinoic acids, the 
glucocorticoid signal dexamethasone enhanced the 
promoter activity of let-7a-1/ let-7f-1 1.91-fold, 2.38-fold 







respectively (Figure 6). Dexamethasone, as a confirmed 
induction agent for apoptosis, has broad application in 
treating cancers (De Bosscher et al., 2000; Riccardi et 
al., 2000; Almawi et al., 2002). Dexamethasone act 
transcriptionally by binding the glucocorticoid receptor 
(GR) and subsequent binding to the promoter region of 
target genes on sites compatible with GRE motifs, which 
in turn directly or indirectly regulated gene expression 
(Almawi et al., 2002). Now the relationship between the 
glucocorticoid signal pathway and miRNAs has aroused 
the interest of investigators. For example, Liao and 
Lonnerdal (2010) found increase of mir-30e in 
dexamethasone-induced IEC-6 cells. Smith et al. (2010) 
studied the microRNA expression and processing during 
lymphocyte apoptosis induced by dexamethasone and 
found that mir-17-92 was repressed significantly (Smith et 
al., 2010). But so far, there is no evidence to support that 
dexamethasone directly activates the transcription 
through GRE within the promoter of microRNA. Thus, in 
our experiment, whether the dexamethasone enhance 
the promoter activity of let-7a-1/let-7f-1 by activate the 
GRE within its promoter need further work to confirm.  
In summary, we determined the transcription start site 
of let-7a-1/let-7f-1 cluster and cloned its 2.1 kb 5’ flanking 
fragment into the pGL3-Basic vector to form the let-7a-
1/let-7f-1 promoter-luciferase reporter construct pGL3-
2123, which represented lower promoter activity that 
consistent with the expression level of let-7a-1/let-7f-1 in 
A549 cells. Preliminary function analysis on pGL3-2123 
revealed that this 2.1 kb promoter of let-7a-1/let-7f-1 was 
transactivated by ectopic expression of c/EBPα or p53. 
Treatment with 9-cis-retinoic acid, all-trans retinoic acid 
or 1,25-(OH)2D3 resulted in little induction of let-7a-1/let-




 M of dexamethasone 
significantly increase the promoter activity of let-7a-1/let-
7f-1, further research should be done to identify the 
responsive functional cis-elements within the let-7a-1/let-
7f-1 promoter and elucidate their regulatory mechanisms, 
thus, providing a foundation for understanding the 
transcription pattern of let-7a-1/let-7f-1 and their 
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